Panc Ca pts w reducd E-cadherin expression had 2.42-fold higher relative risk for death than those w normal expression Halozyme's PegpH20 Restores E-Cad
E-Cadhedrin Expression in Normal and Abnormal Tissue Specimens In Patients with Pancreatic Cancer -journal of laboratory Medicine 2010
The 2-year survival rate of patients with pancreatic carcinoma and reduced or normal E-cadherin expression was 2.7% and 9.5%, respectively. Moreover, patients with reduced E-cadherin expression had a significantly worse prognosis than those with normal E-cadherin expression (log-rank test, χ2=4.267, P=0.039) (Figure 1). In addition, multivariate Cox proportional hazard analysis revealed that E-cadherin expression (P=0.009), CTNND1 expression (P=0.035), lymph node invasion (P=0.011), pTNM stage (P=0.000), and degree of tumor differentiation (P=0.047) were significant independent prognostic indicators of increased 2-year survival, whereas vascular invasion, age, and gender were not (Table 4). Patients with reduced E-cadherin expression had a 2.42-fold higher relative risk for death than those with normal E-cadherin expression.
And you still haven't acknowledged that your position that Hizentra is superior to HyQvia for stockpiling is ridiculous when the non rhuph20 containing Ig requires 20x the number of injections per month which far outweighs any disadvantage readily available refrigeration requirements of HyQ represent. You sound like an anonymous petitioner who LOST their HyQ antigenicity suit and now is spraying your ignorance toward PegpH20- an agent meant to extend life in desperate situations- pancreatic and then lung cancer- not lifelong therapy YET- go pay your legal fees and get back to me on 20:1 injections and stockpiling.
E-cadherin Expression in Normal and Abnormal Tissue Specimens from Patients with Pancreatic Carcinoma
Yang Fei, MSc, Xu-Shun Liu, MSc, Feng Wang, MSc, Wei Wang, MSc, Sheng-Li Liu, MSc
Lab Med. 2010 41(8) 473-477.
Reduced expression of E-cadherin catenin occurred significantly more frequently in poorly differentiated (P=0.023) tissue and in tissue from patients with positive lymph node metastasis (P=0.012), positive distant metastasis (P=0.016), deeper invasion (P =0.044), or advanced stage disease (P=0.041). Additionally, reduced expression of E-cadherin protein in tumor tissue correlated with a worse prognosis and normal expression with a better survival rate (P=0.039). E-cadherin expression was a significant independent prognostic indicator (P=0.009) in pancreatic carcinoma.
Conclusion: The expression of E-cadherin is significantly altered and is closely correlated with the expression of CTNND1, degree of tissue differentiation, pathologic tumor stage, and lymph node metastasis in patients with pancreatic carcinoma. E-cadherin may be the key factor involved in pancreatic carcinoma invasiveness and metastasis.
Loss of E-cadherin expression coincides with the transition from well diff adenoma to invasive carcinoma in a model of pancreatic Ca
A new mechanism of action was published on 7/2/14 by Halozyme scientists concerning their flagship treatment. This reinforcement of cellular adhesion has been shown in pancreratic cancer to stop local invasion and metastases. The cell mambrane component when missing in Pancreatic and NSC Lung Ca results in a greater rate of invasion, mets, and death. Peg restores E-cadherin. Perhaps Someone's getting the message.
Please read a couple of the scientific articles I posted here - tge date if the 1st is 7/24 not 7/2/14 as stated above- you'll see E-cadherin itself is a major prognostic factor in panc Ca. Hyaluronan isn't a binding substance as much as filler - ecad on the plasma membrane us the major adhesion agent.
Accumulation of hyaluronan was associated with loss of plasma membrane E-cadherin and accumulation of cytoplasmic β-catenin, suggesting disruption of adherens junctions. PEGPH20 decreased the amount of nuclear hypoxia-related proteins and induced translocation of E-cadherin and β-catenin to the plasma membrane. Translocation of E-cadherin was also seen in tumors from a transgenic mouse model of pancreatic cancer and in a human non-small cell lung cancer sample from a patient treated with PEGPH20. In conclusion, hyaluronan accumulation by HAS3 favors pancreatic cancer growth, at least in part by decreasing epithelial cell adhesion, and PEGPH20 inhibits these changes and suppresses tumor growth.
CD44 Upregulation in E-Cadherin-Negative Esophageal Cancers Results in Cell Invasion
Grégoire F. Le Bras,
Gillian L. Allison,
Nicole F. Richards,
Shazia S. Ansari,
M. Kay Washington,
Claudia D. Andl mail
Published: November 01, 2011
E-cadherin negatively regulates the interaction of CD44 with hyaluronic acid resulting in a suppression of tumor invasion and cell branching morphogenesis . We show here that the loss of E-cadherin expression correlates with the CD44s form and induction of an invasive phenotype.
(PegpH20 restores E-Cadherin to the plasma membrane, blocking this induction- BioMed Research International
Volume 2014 (2014), Article ID 817613, 15 pages)
My pleasure - the more I dig in the peer reviewed literature on this emerging science, the better pegpH20 sounds.
E-cadherin, the cell membrane glycoprotein responsible for cellular adhesion, is inhibited by chronic exposure to low doses of Cig Smoke- this represents a tie to NSC Lung Cancer ("smoking gun"- sorry couldn't avoid the pun).
Toxicol In Vitro 25,446
PegpH20 Restores cellular E-Cad.
SO, Who gets to come along for the promising trial? Roche's Avastin or Celgene's Abraxane- Or? e will soon find out - Q4 start.
MM-398 will be another Abraxane- Big Price-Little Advantage- Until that is PegpH20 bosts Abraxane in study 202. Leonard Saltz and other leading oncologists have called out Celgene on this pricing. Halozyme will fix it- as a partner or a division (for an order of magnitude richer deal than Merrimack got).
SWOG trial S1313 modifies the problem component 5FU reduces it by 1 infusion - all 4 parts of Folfirinox yield 11 month MOS- why split hairs w 3 parts yielding only 6.1? People are dying- 110 a day in US from panc Ca.
You won't- will be approved on robust - 245 pt- Ph2 data halted on efficacy.
A Study of Perjeta (Pertuzumab) and Herceptin (Trastuzumab) Treatment in Combination With a Taxane in Patients With Advanced HER2-positive Breast Cancer
This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Hoffmann-La Roche
Information provided by (Responsible Party):
First received: December 18, 2013
Last updated: September 22, 2014
Last verified: September 2014
History of Changes
Full Text View Tabular ViewNo Study Results PostedDisclaimerHow to Read a Study Record
This open-label, phase III study will assess the safety, tolerability and effica cy of a combination therapy of intravenous (IV) Perjeta, subcutaneous (SC) Herceptin, and taxane chemotherapy (docetaxel, paclitaxel or nab-paclitaxel) as first
-line therapy in patients with HER2-positive metastatic breast cancer. All patie nts will be treated with 3-week cycles of Perjeta IV (840 mg first dose; subsequ ent doses of 420 mg) and trastuzumab SC (600 mg/5 mL). The taxane treatment regi men will determined by the investigator. Patients will continue therapy until disease progression, unacceptable toxicity, or the patient withdraws consent, whic ever occurs first. Time on study treatment is up to 2 years.
yes and a demonstration of Roche's continued committment to the SC version of their biggest drugs- with HALO taking 5%
I agree- it makes sense for Roche, which makes sense for Halozyme= the point of the post.
To coincide with HyQvia launch? At least an accurate estimate of when- 830!AM EST 866-837-9782 - except for California - he uses his magic 8 ball - told him I was gone